(Eagle News) — The Philippine government has signed an agreement to secure 30 million doses of the COVID-19 vaccine Covovax from the Serum Institute of India.
A statement from the SII’s local partner, Faberco Life Sciences Inc, said the vaccines will be available starting third quarter of this year.
According to Faberco, SII partnered with Novavax, a US-based biotechnology company for the development and commercialization of the Covovax vaccine.
Covovax is so far in third-stage trials and is expected to be approved for use by international regulators.
Once available, the vaccine will be used to inoculate 15 million Filipinos.
So far, three pharmaceutical companies have applied for emergency use authorization of their vaccines in the country.
These are AstraZeneca, Pfizer and Gamaleya.